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Abstract
The human microbiome is of considerable interest to pediatric inﬂammatory bowel disease (PIBD) researchers with 1 potential
mechanism for disease development being aberrant immune handling of the intestinal bacteria. This study analyses the fecal
microbiome through treatment in newly diagnosed PIBD patients and compares to cohabiting siblings where possible. Patients were
recruited on clinical suspicion of PIBD before diagnosis. Treatment-naïve fecal samples were collected, with further samples at 2 and
6 weeks into treatment. Samples underwent 16S ribosomal ribonucleic acid (RNA) gene sequencing and short-chain fatty acids
(SCFAs) analysis, results were analyzed using quantitative-insights-into-microbial-ecology. Six PIBD patients were included in the
cohort: 4 Crohn disease (CD), 1 ulcerative colitis (UC), 1 inﬂammatory bowel disease (IBD) unclassiﬁed, and median age 12.6 (range
10–15.1 years); 3 patients had an unaffected healthy sibling recruited. Microbial diversity (observed species/Chao1/Shannon
diversity) was reduced in treatment-naïve patients compared to siblings and patients in remission. Principal coordinate analysis using
Bray–Curtis dissimilarity and UniFrac revealed microbial shifts in CD over the treatment course. In treatment-naïve PIBD, there was
reduction in functional ability for amino acid metabolism and carbohydrate handling compared to controls (P= .038) and patients in
remission (P= .027). Metabolic function returned to normal after remission was achieved. SCFA revealed consistent detection of
lactate in treatment-naïve samples. This study adds in-depth 16S rRNA sequencing analysis on a small longitudinal cohort to the
literature and includes sibling controls and patients with UC/IBD unclassiﬁed. It highlights the initial dysbiosis, reduced diversity,
altered functional potential, and subsequent shifts in bacteria from diagnosis over time to remission.
Abbreviations: CD = Crohn disease, IBDU = inﬂammatory bowel disease unclassiﬁed, PIBD = pediatric inﬂammatory bowel
disease, PiCRUSt = phylogenetic investigation of communities by reconstruction of unobserved states, QIIME = quantitative-
insights-into-microbial-ecology, SCFA = short-chain fatty acid, UC = ulcerative colitis.
Keywords: 16S, Crohn disease, inﬂammatory bowel disease, microbiome, pediatrics
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Ashton et al. Medicine (2017) 96:26 Medicinean increasing incidence of PIBD within the United Kingdom but
the reasons behind this remain unclear.[3,4]
The microbiome is of considerable interest to inﬂammatory
bowel disease (IBD) researchers. The intestinal microbiome
consists of luminal and mucosal communities[5]; a possible
mechanism for disease development in PIBD is aberrant immune
handling of the microbiome resulting in inﬂammation[6]; alterna-
tively, a dysbiosis in the microbiota may trigger disease in
immunologically normal individuals.[7] Several studies focussing
on the treatment naïve (TN) pediatric CD patient have made
observations of signiﬁcant mucosal microbial dysbiosis compared
to healthy controls,[8,9] and this dysbiosis has also been observed in
historically diagnosed, active PIBD.[10,11] Some studies comparing
the fecal and mucosal microbiome have demonstrated differences
in the fecal organisms seen in PIBD cases and controls,[10–13]whilst
others have shown little variation.[8] It is widely accepted that
alterations in the mucosal microbiome are more pronounced than
those observed in the fecal microbiome.[8,12]
Despite the intense interest in the role of the microbiome in
PIBD, there have been few longitudinal studies.[14] Dysbiosis of
the gut microbiota in pediatric CD patients treated with exclusive
enteral nutrition (EEN) has been broadly demonstrated in
patients using denaturing gradient gel electrophoresis[15] and
more recently through next-generation sequencing, including
metagenomic analysis.[14,16]
With the advent of high-throughput next-generation 16S
rRNA gene sequencing, the microbiome can now be character-
ized in depth and detail that was not previously available.[8] This
study analyses the fecal microbiome from prediagnosis to 6weeks
of treatment in newly diagnosed, TN pediatric IBD patients, and
additionally compares individuals to cohabiting sibling controls
where available.
2. Materials and methods
All patients were recruited following referral to Southampton
Children’s Hospital. The pediatric gastroenterology service at
Southampton diagnoses approximately 60 to 70 new cases of
PIBD every year. Diagnosis was based on the Porto criteria.[17]
Six PIBD patients were recruited, of whom 2 were male.
Subsequent diagnosis indicated that 4 had CD, 1 UC, and
1 IBD unclassiﬁed (Table 1). Themedian age at diagnosis was 12.7
years. Patients with a suspected diagnosis of PIBD were recruited
after the initial clinic visit, before investigation or treatment.
Speciﬁc histological diagnosis was obtained within 2 weeks for all
patients. Fecal sampleswereobtainedbefore the commencementof
treatment, and at 2 to 4 weeks and 6 to 8 weeks postdiagnostic
endoscopy. Clinical data on disease activity, including fecal
calprotectin, were collected prospectively at each visit.
Single-control samples were obtained from siblings living
within the same household at the time of their sibling’s diagnosis.
2.1. Ethical approval
The study has ethical approval from Southampton& SouthWest
Hampshire Research Ethics Committee (09/H0504/125). This
study was conducted in accordance with relevant guidelines, all
protocols were approved by the ethics committee above and
informed consent was obtained from all subjects.
2.2. Sample collection
Samples were collected using a commode specimen collection kit
(Ardinal). All samples were processed within 24 hours. Before2
Ashton et al. Medicine (2017) 96:26 www.md-journal.comprocessing and during transit all samples were in sealed
containers with some air and kept on ice in an insulated cool-
bag at a temperature estimated to be less than 8 °C.
2.3. Sample processing
Samples were homogenized. Two grams of feces was immediately
frozen at 80 °C for short-chain fatty acid (SCFA) analysis. Five
grams of feces was separated for further processing. A unit of 10
mL of phosphate buffered saline/30% glycerol solution was
added and samples were further homogenized using sterile glass
beads and vortex, these samples were then frozen immediately at
80 °C in 450-mL aliquots.
2.4. DNA extraction and 16S rRNA gene sequencing
Deoxyribonucleic acid (DNA) was extracted using MP Biomedi-
cal (Santa Ana, California) Feces Extraction kit following the
manufacturer’s instructions. An amount of 20ng of extracted
DNA underwent processing at Source Bioscience (Nottingham,
UK). The V4 area was targeted by ampliﬁcation using the
degenerate primers (forward TATGGTAATTGTGTGCCAGC-
MGCCGCGGTAA, reverse AGTCAGTCAGCCGGACTACH-
VGGGTWTCTAAT). polymerase chain reaction (PCR) products
were between 300 and 350bp in length with an individual sample
barcode incorporated into the reverse primer. PCR fragments
were then sequenced on an IlluminaMiSeq with 2 150-bp paired-
end reads. Steps in sequencing were as follows: 1st stage PCR,
PCR clean-up, 2nd stage PCR, PCR clean-up 2, library
quantiﬁcation and normalization, library denaturing, and MiSeq
sample loading at 10pM.
2.5. Bioinformatics—microbiome analysis
16S rRNA gene sequencing data were processed using the
quantitative insights into microbial ecology (QIIME) analysis
pipeline. Bacterial community composition of a sample is
achieved by clustering reads into operational taxonomic units
and assigning taxonomy using the Greengenes (gg_13_8)
database of 16S rRNA sequences.[18] Clustering was performed
using a 97% similarity index, thereby allowing identiﬁcation of
some bacteria to the species level. Further analysis of alpha and
beta diversity was performed using QIIME.
2.6. Functional analysis
Metagenomic inference and functional analysis was performed
using phylogenetic investigation of communities by reconstruc-
tion of unobserved states (PICRUSt).[19] PICRUSt utilizes a
computational approach and predicts a metagenome using 16S
data, from this it predicts which genes are present and thus
predicts functional composition of the metagenome. Pathway
analysis was conducted using Kyoto Encyclopaedia of Genes and
Genomes (KEGG) pathways.[20]
Output data from PICRUSt were ﬁltered for metabolic
pathways as these are assumed to be the most relevant for
IBD.[8] Median gene counts from patients at each time point (TN,
control, and remission) were compared. Differences were
calculated between time points for each metabolic pathway to
estimate functional differences in the microbiome.
2.7. Fecal calprotectin measurements
Estimation of Calprotectin concentrations were carried out using
the CALPROLAB Calprotectin enzyme-linked immunosorbent3assay (ELISA) (ALP) kit (Lysaker, Norway) and Calpro Fecal
Extraction Device (Lysaker, Norway). A unit of 100mg of
homogenized feces was dispersed in 4.9mL of extraction buffer
by vortexing for 3 minutes. The fecal extract and standards were
assayed by sandwich ELISA following the manufacturer’s
instructions. Sample values were calculated by comparison with
standard curve plots prepared using the calprotectin standards
provided in the kit.2.8. SCFA analysis
Aliquots of homogenized fecal samples (∼1g) were mixed with
sterile H2O (1:3w/v), vortexed for 2 minutes, centrifuged for 10
minutes at 1000g, and the supernatant collected and frozen.
Fecal acetate, propionate, butyrate, lactate, and total SCFAs were
subsequently quantiﬁed in duplicate using capillary gas chroma-
tography with 0.1mol/L 2-ethyl butyric acid as an internal
standard, as described previously.[21]2.9. Statistics
Statistical analysis was with Shapiro–Wilk normality test (in
order to test the distribution of data), Student t test (alpha
diversity), and Mann–Whitney U test (comparison of groups in
functional analysis) and was performed using SPSS v22 (IBM,
North Castle, NY).3. Results
Six PIBD patients were recruited; 4 CD, 1 UC, and 1 IBD
unclassiﬁed (Table 1). Two were male. Median age at diagnosis
was 12.7 years. All patients were diagnosed according to the
modiﬁed Porto criteria.[17] Three of these patients had a healthy
sibling control recruited simultaneously (fecal calprotectin values
were 120, 32, and 24mg/kg for sibling controls of patients 1–3,
respectively). All recruited siblings were reported to be well at the
time of investigation and have not developed PIBD subsequently.
All patients provided fecal samples before commencement of
bowel preparation for diagnostic endoscopy and further fecal
samples at 2 weeks (median 14 days, range 12–25 days) and
6 weeks (median 41 days, range 36–49 days) after commence-
ment of treatment. These 21 samples were characterized for
microbiome composition, fecal calprotectin, and SCFA concen-
trations (18 IBD, 3 sibling controls).3.1. Disease activity and treatment
Disease activity and remission was assessed by physician
assessment and subsequently in conjunction with fecal calpro-
tectin levels (Fig. 1). Fecal calprotectin is a marker protein for
colonic inﬂammation which can be stably detected in feces.
Patients were treated with either EEN (Modulen; Nestle,
Switzerland) or corticosteroid therapy, depending on disease type
and site, in accordance with national guidelines.[22,23] In all cases,
treatment was started within 24 hours of diagnosis (based on
endoscopy ﬁndings).3.2. Microbial composition analysis
A heatmap of common genera produced by Bray–Curtis
dissimilarity (see below) can be seen in Fig. 2. This details the
most common species seen across all samples and the relationship
between samples and bacteria.
Figure 1. Changes in fecal calprotectin across time. Solid line demonstrates the threshold for active intestinal inﬂammation (>200mg/kg), with the normal range 5
to 50mg/kg. Patient numbers correspond to those described in Table 1.
Ashton et al. Medicine (2017) 96:26 MedicineThere was signiﬁcant variation between all samples with
signiﬁcant intraindividual variation. Several patients had
distinct microbiota at diagnosis. For example, patient 1 and
their sibling control had large numbers of Prevotella species
(66% and 60%, respectively). These siblings are of Nigerian
ethnicity but were born in the United Kingdom, and these
bacteria are known to be associated with a high-ﬁber “rural
African diet.”[24] With EEN, this genus rapidly decreased overFigure 2. Heatmap of common genera in all samples across treatment produced u
genera (white is most abundant). The degree of similarity of microbiota can be obse
be observed using the dendrogram on the y-axis.
42 weeks to below 0.0006%. Patient 2 (white British) had 35%
Prevotella at diagnosis, again declining with EEN treatment.
No other patient had greater than 13.5% prevalence of
Prevotella at diagnosis. Patient 5’s (UC) treatment-naive sample
was also distinctive with a high proportion of Streptococcus
(and Proteobacteria) in comparison to the other patients; at a
genus level, this patient had 37% Streptococcus and 18%
Sutturella.sing Bray–Curtis dissimilarity—lighter colors indicates more abundance of that
rved using the dendrogram on the x-axis. The degree of similarity of sample can
Table 2
Mean alpha diversity measures for PIBD patients and controls
through treatment and by treatment type—increasing diversity
through treatment.
Observed species Chao1 Shannon
All samples
Mean diagnosis 9064 26,334 4.92
Mean 2wk 9505 28,076 5.59
Mean 6wk 10,958 31,480 5.56
Mean controls 11,119 32,685 5.6
Diagnosis vs 6wk P= .108 P= .076 P= .368
Diagnosis vs controls P= .306 P= .336 P= .245
EEN
Mean diagnosis 8780 25,431 4.84
Mean 2wk 9729 28,478 5.69
Mean 6wk 9599 29,054 5.20
Corticosteroids
Mean diagnosis 9349 27,238 5.00
Mean 2wk 9282 27,675 5.50
Mean 6wk 12,317 33,907 5.92
Statistical comparison by Student’s t-test. EEN= exclusive enteral nutrition.
Ashton et al. Medicine (2017) 96:26 www.md-journal.comAfter remission was reached (at 2–6 weeks, see Table 1), the
most commonly occurring bacteria were generally altered. There
were increased numbers of Bacteroides in all patients, Clostridi-
um classes were still prevalent but included a greater diversity
of species. There was also an expansion of Biﬁdobacterium in
3 patients.Figure 3. (A) Observed species for individual patients across treatment, (B)
Chao1 diversity for individual patients across treatment, (C) Shannon diversity for
individual patients across treatment. (○ Indicates patients who went into
remission at 2 weeks,□ indicates patients who went into remission at 6 weeks).3.3. Alpha diversity
Three measures were used to analyze species diversity within
samples. Data were normally distributed. The mean results can be
seen in Table 2. All 3 measures (observed species, chao1, and
Shannon diversity) show an increase in diversity from diagnosis
throughout treatment, although none reach statistical signiﬁcance
(Table 2). Controls have increased alpha diversity compared to
patients at any time point, but this is not statistically signiﬁcant.
Samples at 6weeks postdiagnosis,when all patientswere in clinical
remission, have the most similar diversity metrics to controls.
3.4. Individuals during treatment
Alpha diversity for all PIBD patients across the 3 time points can
be seen in Fig. 3A to C. There is signiﬁcant variation within the
mean values with a tendency toward increased diversity across
treatment.
3.5. Treatment type
Results were collated by treatment type. Increases in diversity
from diagnosis to remission were observed for those treated with
both EEN and steroid therapy (Table 2).
3.6. Antibiotics
Therewere 3 patientswhohadbeen treatedwith antibiotics in the 6
weeks before initial sample (2 with metronidazole, 1 with
amoxicillin). These were patients 2, 4, and 5. Comparing alpha
diversitymeasures at diagnosis between thesepatients and thosenot
treated with antibiotics showed decreases in the average number of
observed species (antibiotics 9096 vs noantibiotics 10,333), Chao1
(26,110 vs 31,150), and Shannon diversity (5.15 vs 5.57).53.7. Compositional changes in microbiota
Principal coordinate analysis (PCoA) was undertaken for all
samples following analysis through application of Bray–Curtis
dissimilarity (Fig. 4A, BC, compositional dissimilarity between
samples), unweighted UniFrac (Fig. 4B, UU, diversity between
samples incorporating relative relatedness) and weighted UniFrac
(Fig. 4C, WU, diversity between samples incorporating relative
relatedness and relative abundance).
Both Bray–Curtis and UniFrac PCoA revealed high similarity
between patient 1 (at diagnosis) and their sibling control, and
patient 3 (at diagnosis) and their sibling control.
Patients with CD or UC showed a distinct shift on PCoA (BC,
UU, and WU) from diagnosis to treatment. The single patient
Figure 4. (A) Principal coordinate analysis (PCoA) Bray–Curtis dissimilarity PC1 vs PC2, D=before diagnosis, 2=2 weeks into treatment, 6=6 weeks into
treatment, C=control. For patients details please see Table 1. (B) PCoA weighted UniFrac PC1 vs PC2, D=before diagnosis, 2=2 weeks into treatment, 6=6
weeks into treatment, C=control. For patients details please refer to Table 1. (C) PCoA unweighted UniFrac PC1 vs PC2, D=before diagnosis, 2=2 weeks into
treatment, 6=6 weeks into treatment, C=control. For patients details please refer to Table 1.
Ashton et al. Medicine (2017) 96:26 Medicinewith IBDU (patient 6) did not show any discernible shift with all 3
time points clustering on PCoA (Fig. 4A).3.8. Metagenomic and functional analysis
Output data fromQIIMEwas analyzed using PICRUSt enabling
themetagenomicmake-up of samples to be inferred from the 16S
data. A total of 147 metabolic pathways were identiﬁed by
PICRUSt (see Supplementary Table 1, http://links.lww.com/
MD/B779). Subsequent analysis looked at the functional impact
of microbial shifts. Comparison of TN patients at diagnosis
with control samples and with samples from the patients in
remission showed signiﬁcantly different metabolic function
across the 147 KEGG pathways identiﬁed, as assessed by gene
copy number (P= .038 and .027 respectively) (Fig. 5). Patients in6remission and controls showed no differences in metabolic
function as assessed by gene copy number across the 147 KEGG
pathways (P= .86). There were large differences (predicted
functional reduction >30%) in 31 pathways between TN
patients and both controls and patients in remission. An
additional 36 pathways displayed a predicted functional
reduction of between 10 and 30%. Speciﬁcally there were large
reductions in amino acid synthesis and metabolism pathways
(particularly in those associated with arginine, proline, lysine,
valine, leucine, and isoleucine) and in carbohydrate handling,
particularly in pathways associated with fructose, mannose,
galactose, starch, and sucrose metabolism. There was also a
predicted reduction in nucleotide (purine and pyrimidine)
metabolism and decreased nitrogen metabolism in treatment
naive patients.
Figure 5. Comparison of 147 common metabolic pathways in IBD fecal microbiome samples-markers indicate absolute difference in predicted function (gene
copy number) between samples, a value of 0 indicates no difference in predicted function (gene copy number). Negative difference in gene copy numbers indicate
loss of function in treatment-naïve (TN) patients in that metabolic pathway. Differences are calculated by subtracting the predicted gene copy number in 1 group
from another (refer to this ﬁgure). For example, the metabolic pathway associated with purine metabolism (ﬁrst pathway on x-axis) displayed the greatest loss of
function in TN samples compared to both control samples and samples from patients in remission. There was a median reduction of3391,471 (TN—control) and
356,6025 (TN—remission) gene copies between samples indicating signiﬁcantly reduced functional capability in this metabolic pathway in patients with TN IBD.
Controls and patients in remission were not statistically different (P= .86). There are statistically signiﬁcant differences in function (gene copy number) between both
TN and controls (P= .038), and TN and patients in remission (P= .027) across all 147 Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways. Statistical
analysis was with Shapiro–Wilk normality test (distribution of data) andMann–WhitneyU test (functional analysis). Please refer to Supplementary table 1, http://links.
lww.com/MD/B779 for clariﬁcation of KEGG pathways and exact gene copy number differences.
Ashton et al. Medicine (2017) 96:26 www.md-journal.com
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Ashton et al. Medicine (2017) 96:26 Medicine3.9. Short chain fatty acid analysis
The fecal samples were analyzed for SCFA content (patient 5’s 6-
week sample was unsuccessful) (Fig. 6). In all samples the
predominant SCFAs were acetate, propionate and butyrate, in
that order of abundance. Over treatment, there were no dramatic
shifts in relative concentrations of SCFA, and no consistent effects
of either EEN or steroid treatment. Levels of succinate increased
in patients 2 and 3 when remission was reached. Lactate was
detected in all the samples (median concentration=2.45mmol/
L), while it is often undetectable in studies of healthy individuals.
In patient 5, there was a comparatively large amount of lactate
before diagnosis (29.3mmol) which disappeared after 2 weeks of
treatment. Patient 1 also had high lactate (15.3mmol) concen-
trations at diagnosis which again decreased during treatment, this
time with an associated rise in butyrate concentrations.
3.10. SCFA and functional analysis
Of the 147 metabolic pathways identiﬁed, those implicated in
SCFA were examined. Two pathways (Butyrate metabolism and
Propionate metabolism) were seen to be reduced in TN patients
compared to controls. The relative abundance of these SCFA was
observed; there were no statistically signiﬁcant differencesFigure 6. Fecal short-chain fatty acid relative concentration over time in pediatric in
to Supplementary table 2, http://links.lww.com/MD/B779.
8between TN patients and controls/patients in remission. Propio-
nate relative abundance was slightly decreased (TN 20.4% vs
control/remission 18.1%), Butyrate was slightly increased
(TN 11.8% vs control/remission 13.6%) and isobutyrate was
also slightly increased (TN 2.1% vs control/remission 2.3%)
(Fig. 6).4. Discussion
This study details sequential analysis of the fecal microbiome of
6 PIBD (including CD, UC, and IBDU) patients treated with
standard therapies over a 6-week period. Our study provides in-
depth analysis of the fecal microbiome in newly diagnosed TN
PIBD patients and follows these through to remission. These
results, including clear microbial shifts and detailed functional
analysis, suggest similar examination of larger numbers of
patients could give insight into the etiology of IBD. The utilization
of sibling controls is novel, and it was hoped this would reduce
the natural variation seen in the fecal microbiome caused by diet
and environment.[25] The value of this is apparent with the very
high incidence of Prevotella observed in both patient 1 and their
sibling control. Overall, the data generated in this study are
valuable but further patient numbers are required to produce ﬁrm
conclusions.ﬂammatory bowel disease patients and controls—for absolute abundance refer
[28]
Ashton et al. Medicine (2017) 96:26 www.md-journal.comPrevious studies have demonstrated a reduction in bacterial
diversity in TN children with CD.[14–16] We have shown similar
proﬁles for all PIBD patients, there was reduced alpha diversity
(consistently observed by 3 measures-observed species, Chao1,
and Shannon index) in treatment naive patients compared to the
same patients when remission was achieved. Both patient
treatment groups, EEN and corticosteroids, had an increase in
diversity for all measures (other than Shannon index in those
treated with corticosteroids) during the treatment course.
Beta diversity was assessed through Bray–Curtis dissimilarity
index and through weighted and unweighted UniFrac analysis.
For all patients, other than patient 5 (UC), there are clear shifts on
all analyses from before diagnosis to after treatment. Generally
there was clustering of patients 1, 2, 3, and 4 (all CD) after
treatment (samples at 2 and 6 weeks) for both Bray–Curtis and
UniFrac PCoA, although this was not ubiquitous for all principal
coordinates. Patient 5 (UC) showed similar shifts in PCoA
analysis to the patients with CD, whereas there were no shifts for
patient 6 (IBDU) with clustering of samples from all 3 time
periods in all analyses. Interestingly, controls were generally
closely related to their affected sibling; with the closest clustering
occurring between PIBD samples before diagnosis and their
sibling control. This was especially evident for patients 1 and 3
who were closely related on both Bray–Curtis and unweighted
UniFrac PCoA.
The predicted metabolic function of the microbiome was
assessed. Despite low patient numbers, it appears that there is a
clear difference in functional capability between the microbiome
in TN patients and the same patients after they have gone into
remission. Patients in remission resemble controls in terms of
functional proﬁle. Previous metagenomic analysis has character-
ized the functional changes of mucosal microbiome samples in
CD, displaying clear evidence that there is reduced amino acid
biosynthesis and carbohydrate metabolism.[12]
This study has, for the ﬁrst time, compared the functional
ability of the microbiome before treatment to the functional
ability in the same patients once they have achieved remission
through inference of the metagenome by PICRUSt. Genes
involved in both amino acid biosynthesis and metabolism, and
carbohydrate metabolism (speciﬁcally starch, sucrose, fructose,
and mannose metabolism) were less abundant in the pretreat-
ment samples when the disease was active than in the later
samples taken during remission. Interestingly, the functional
ability of the microbiome returns to a state very similar to that of
controls when remission is achieved. Where there is signiﬁcant
inter and intrapatient heterogeneity in the bacterial species
present in IBD before and after treatment, these results indicate
that there is relative functional homogeneity.
This study also looked at SCFA concentrations in feces over
time. Previous work has suggested a role for speciﬁc SCFA as
anti-inﬂammatory agents within the bowel.[26,27] The most
common metabolic products of anaerobic bacteria are acetate,
propionate and butyrate and these have been suggested to impact
on the interaction that the immune system has with bacteria
producing these SCFAs, with the overall effect of reducing
inﬂammation through reduction of chemokine production and
adhesionmolecule expression.[27] The predominant SCFAs in our
samples were acetate, propionate and butyrate, including in
controls. The relative concentrations of these SCFA over time
did not show a consistent pattern with some patients seeing
increases and some seeing decreases in both overall and relative
concentrations. High concentrations of lactate, which has been
implicated in UC were observed in the pretreatment samples for9this patient only. It is worth noting that SCFA detection in
fecal samples is affected by both production and absorption of
SCFAs in the large intestine. During disease remission the
intestinal epithelial surface is less inﬂamed and may absorb more
SCFA, so the absence of detectable changes in concentrations
may not necessarily mean that bacterial fermentation has not
changed.
The microbiome has previously been assessed in large cohorts
of TN CD patients.[8,11] These have concluded that there is
signiﬁcant dysbiosis in ileal and rectal mucosal biopsy samples
which is more weakly reﬂected in the fecal microbiome.[8,12] The
same studies have also described shifts in the predominant
bacterial species in diseased patients, with a general change to
aerobic species in the feces as inﬂammation increases.[29] Our
results indicate a similar shift with an increase in the anaerobic
Clostridia and Bacteroides species from diagnosis to remission.
It should be noted that the microbiota of fecal samples may be
inﬂuenced by bowel preparation medication up to 2 to 4 weeks
after administration.
Some studies have followed children with CD from diagnosis
through treatment with EEN.[14,16,30] Most of these studies have
reported a decrease in diversity during treatment with EEN; our
results demonstrate a different pattern over the period of EEN,
with an increase in diversity, peaking at 2 weeks. Interestingly,
children treated with steroids also showed increased diversity
from treatment to remission, with a peak in diversity at 6 weeks.
The reasons behind this are unclear. There were 3 patients treated
with antibiotics in the 2 months before recruitment (patients 2, 4,
and 5); antibiotics are known have a signiﬁcant impact on
intestinal bacteria and may amplify intestinal dysbiosis in some
cases.[8,31]
The strengths of this study lie in the robust and consistent data
and sample collection by a single center, and the linked
assessment of both microbial composition and activity. The
main limitation is the small patient number and heterogeneity of
the population. Despite this, we present detailed analysis of 16S
rRNA sequencing data to a level not previously described in
patients followed across time during treatment. There is little
published data on the microbiome in Ulcerative Colitis or IBDU,
Gevers et al[8] included a small number of UC patients in their
extended PCoA analysis in 2014 without obvious trends. Here
we demonstrate a single patient with IBDU over time, whose
microbiome appears to behave differently to patients with CD
and UC in this study. The PCoA shift for the patient with UC
resembles CD; whilst a previous study indicated substantial
dysbiosis in fecal samples from children with severe colitis there
have been no longitudinal studies of UC to date.[10]5. Conclusion
These data add in-depth 16S rRNA gene sequencing analysis on
a longitudinal PIBD cohort, including patients with UC/IBDU
to the literature. The inclusion of sibling controls helps to
address differences that may be diet related. It highlights the
initial dysbiosis, reduced diversity with dominance of single
bacterial genera, and subsequent shifts in bacteria from before
diagnosis over time to remission. Further characterization of the
SCFA composition of feces would aid understanding of the roles
SCFA may play in intestinal inﬂammation and microbe–host
interaction. The functional ability of bacteria at presentation
is signiﬁcantly reduced in several key pathways; however,
this returns to normal when remission is achieved, echoing
previous ﬁndings targeting the mucosal microbiota. Further
[16] Kaakoush NO, Day AS, Leach ST, et al. Effect of exclusive enteral
Ashton et al. Medicine (2017) 96:26 Medicinelongitudinal studies on larger pediatric cohorts is required
within this area.References
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